A viewpoint about Lenadogene nolparvovec failing to meet its primary endpoint even though it permanently corrects the m.11778G>A mutation causative of LHON

Eye (Lond). 2025 Aug;39(11):2110-2111. doi: 10.1038/s41433-025-03856-5. Epub 2025 May 20.
No abstract available